Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism GluN2A modulators(glutamate ionotropic receptor NMDA type subunit 2A modulators), GluN2B agonists(Glutamate [NMDA] receptor subunit epsilon 2 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Preclinical | CN | 30 Nov 2022 |